Glaucoma Treatment to Go Cosmetic and Boost Eyelashes
A panel of experts for the U.S. Food and Drug Administration (FDA) stated that a current glaucoma treatment is safe and effective enough to be used to make eyelashes fuller and longer. The panel recommended to the FDA that the drug from Allergen be approved for cosmetic use, with the requirement of follow-up testing after the product's release.
Fuller Eyelashes Is a Marketable Side Effect
During studies of Allergen's Lumigan® for treatment of eye conditions stemming from glaucoma, researchers noticed that, as a side effect, the drug seemed to stimulate eyelash growth. Seeing the revenue potential of a medical eyelash enhancer, Allergen pursued marketing a cosmetic version of Lumigan®.
Lumigan® vs. Latisse®
Allergen plans to market the cosmetic version of the drug under the name of Latisse® and is seeking FDA approval for the drug to be prescribed by any licensed physician to patients who are 18 years of age or older.
Will the FDA Follow the Panel's Suggestion?
The FDA is not required to follow the recommendation of the Dermatologic and Ophthalmic Drugs Advisory Committee (the review panel). However, typically the agency tends to agree with the panel's recommendation. The FDA is expected to make a decision on Latisse® in the middle of 2009.
Want More Information?